Biofrontera Initiates Prompt Ameluz® Recall Over Packaging Defects

Biofrontera (BFRI) has released an update.

Biofrontera, Inc. has announced a recall of select lots of Ameluz® due to packaging defects from an external supplier. The recall is not expected to affect patients’ health and the company will replace the affected products promptly. Financially, Biofrontera will not be responsible for recall costs and does not foresee any significant financial impact from this incident.

For further insights into BFRI stock, check out TipRanks’ Stock Analysis page.